Latest news with #EBRSystems
Business Insider
3 days ago
- Business
- Business Insider
Bell Potter Reaffirms Their Buy Rating on Trajan Group Holdings Ltd (TRJ)
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Trajan Group Holdings Ltd (TRJ – Research Report), with a price target of A$1.50. Confident Investing Starts Here: Jacobs covers the Healthcare sector, focusing on stocks such as EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, Trajan Group Holdings Ltd, and Medical Developments International Limited. According to TipRanks, Jacobs has an average return of -21.3% and a 13.92% success rate on recommended stocks. Trajan Group Holdings Ltd has an analyst consensus of Moderate Buy, with a price target consensus of A$1.53. The company has a one-year high of A$1.31 and a one-year low of A$0.72. Currently, Trajan Group Holdings Ltd has an average volume of 29.48K.
Business Insider
6 days ago
- Business
- Business Insider
Wilsons Sticks to Their Buy Rating for EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)
Wilsons analyst Shane Storey maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report) yesterday and set a price target of A$3.00. The company's shares opened today at A$1.09. Confident Investing Starts Here: Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. According to TipRanks, Storey has an average return of 7.5% and a 50.62% success rate on recommended stocks. EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Strong Buy, with a price target consensus of A$2.80, implying a 156.88% upside from current levels. In a report released on May 25, Bell Potter also maintained a Buy rating on the stock with a A$2.25 price target. The company has a one-year high of A$2.08 and a one-year low of A$0.82. Currently, EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 1.08M.
News.com.au
26-05-2025
- Business
- News.com.au
Health Check: The endo-metriosis? Proteomics is on the case
Having produced more positive diagnostics results, Proteomics plans to launch its Promarker Endo device locally this year Immutep posts more positive trial results, this time for soft tissue sarcoma Broker values EBR Systems share price at more than double current worth after capital raising Proteomics International Laboratories (ASX:PIQ) has come up with more positive data to support its endometriosis diagnosis test Promarker Endo, presented – aptly – to the World Congress on Endometriosis, held in Sydney over the weekend. Affecting one in nine women and girls, endometriosis is a common and painful disease that occurs when tissue similar to the lining of the uterus grows in other parts of the body. The condition takes on average seven years to diagnose, owing to the need for an invasive laparoscopy followed by histopathology (a camera is inserted into the pelvis through a small cut in the abdominal wall). The condition is often misdiagnosed. Promarker Endo is a non-invasive alternative, providing a 'traffic light' risk score of low, moderate to high. Derived from analysing 704 plasma samples, the latest results follow those of a 'breakthrough' study of 805 samples in December last year. The latest results showed an 83-98% ability to detect the disease and a 95% ability to rule it out. The company says the results shows that Promarker Endo 'demonstrates high diagnostic accuracy across all stages of endometriosis using a single universal test.' The company plans to launch Promarker Endo locally, in the September quarter. Immutep reports more promising cancer trial results When it comes to its lead compound dubbed 'efti', immuno-oncology drug developer Immutep (ASX:IMM) can't be accused of depriving investors of news flow. Immutep shares surged up to 11% after the company reported 'remarkable' patient response rates in a German lung cancer trial. Today, the company said a phase II soft tissue sarcoma trial hit its primary endpoint, when combining efti with radiotherapy and the standard of care checkpoint inhibitor, Keytruda. A rare cancer, soft tissue sarcoma starts in the soft tissues of the body, including muscle, fat, nerves, blood vessels, and tendons. The investigator-led trial exceeded the study's prespecified median of 35% tumour hyalinisation/fibrosis, versus 15% for historical data from radiotherapy alone in patients with resectable (operable) soft tissue sarcoma. Tumour hyalinisation/fibrosis is an early surrogate endpoint at the time of surgical resection that has been associated with improved overall survival and recurrence-free survival. Hyalinisation is a process where normal tissue degenerates into a translucent material called hyaline. So, while hyalinsation/fibrosis seems like a 'bad' thing, the presence of it leads to a heightened anti-cancer response. Enrolling 40 patients in January this year, the investigator-led trial was carried out at Warsaw's Maria SkÅ‚odowska-Curie National Research Institute of Oncology. Immutep is also trialling efti, a so-called Lag-3 protein, for other solid tumours including non-small cell lung cancer, head and neck squamous cell carcinoma and metastatic breast cancer. EBR shares find their groove Fresh from EBR Systems' (ASX:EBR) $56 million capital raising last week, broker Canaccord values the company's stock at $2.50 per share, more than double their current worth. By way of a placement, EBR's whip-'round was carried out to fund the US commercialisation of its Wise left-ventricle pacemaker, which the US Food & Drug Administration (FDA) approved in mid-April. Now comes the equally hard part of convincing surgeons and obtaining reimbursement. On the latter, Canaccord says EBR is on track to obtain full reimbursement by October 1, for both inpatients and outpatients. The firm believes some surgeons and hospitals won't wait until then, with the first procedures likely in early August. 'Recent clinician discussions have suggested US hospitals are willing to absorb the cost of Wise pre reimbursement, for patients with a lack of alternative solutions.' In other words: 'if you can't pay, don't worry – we will spot you'. While the initial implants are likely to amount to only a handful, they will show the 'excitement about Wise among clinicians and patients'. Announced last Thursday, the placement was executed at $1 a share, a circa 18% discount on the frozen price of $1.215. The stock initially was sold down to $1.06 but is now trading above the pre-placement price. The shares were sold off sharply post FDA approval, partly reflecting expectations of a capital raise. EBR has US$84 million in the bank, but Canaccord's valuation assumes the issuance of a further 105 million shares in a follow-on raising, in 2025-26 or 2026-27. Medical devices 'safe haven' Canaccord notes that medical device makers generally have proved a haven in the US market turmoil, outperforming both the healthcare index and the S&P 500 index. US-listed device makers have gained 7.7% since the start of the year, compared with a 1.4% gain for the S&P 500 and a 3.3% decline for the proxy index, the Ishares US medical device ETF. ASX device makers have enjoyed a purple patch, with the FDA approving Orthocell's (ASX:OCC) Remplir nerve regeneration device in early April. In March the agency green-lit Nanosonics' (ASX:NAN) next-gen medical probe steriliser, Coris and Artrya's (ASX:AYA) AI-enabled coronary plaque detection tool. Medical devices don't tend to offer the same upside as an approved drug, but they are far less risky proposition. While-no one quite knows what's going on in the mind of Donald Trump, they are not in the firing line in the same way as overseas (notably European) drug makers. Rhythm nails it with 'poo test' alternative There's more on the diagnostics front, with Rhythm Biosciences (ASX:RHY) completing testing the second stage of testing of Colostat, its blood-based test for bowel cancer. Using banked patient samples, the second-generation (beta) kit generated around 23,000 data points 'to evaluate a variety of variables including inter and intraplate precision, interference and detection limits'. More than 96% of the total tests 'comfortably met the performance targets for their operational use.' The remaining 4% will be 'compensated for' in the final, manufactured product. In short, the test meets the 'performance required to meet or exceed the proposed clinical use as a triage test for patients symptomatic for bowel disease'. The next step involves Rhythm's partner Quansys producing pilot kits, followed by final testing with independent clinical samples. 'Following completion of the above, Rhythm will be able to make Colostat commercially available through Rhythm's commercial laboratory.' This would be by way of National Association of Testing Authorities verification, or through partner laboratories using their own accreditation. Ultimately, the assay aims to replace the current 'poo test', which many users find cumbersome, abhorrent for cultural reasons or simply unattractive.
Business Insider
26-05-2025
- Business
- Business Insider
Bell Potter Reaffirms Their Buy Rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report), with a price target of A$2.25. The company's shares closed last Friday at A$1.21. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Jacobs is ranked #9406 out of 9536 analysts. Currently, the analyst consensus on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is a Strong Buy with an average price target of A$2.80, representing a 131.40% upside. In a report released on May 23, Canaccord Genuity also maintained a Buy rating on the stock with a A$2.50 price target. The company has a one-year high of A$2.08 and a one-year low of A$0.82. Currently, EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 995.8K.
News.com.au
23-05-2025
- Business
- News.com.au
Scott Power: ASX health stocks rise with capital raisings in full swing
ASX health stocks up 0.57% over past week, while the broader market is up 0.35% Wave of capital raisings as ASX-listed healthcare firms seek to strengthen their balance sheets Monash IVF's woes continue with company downgrading FY25 blaming softer market Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick. Power said there had been a plethora of capital raisings over the past couple of months as ASX healthcare companies look to replenish their cash reserves. In the latest capital raise announcements, EBR Systems (ASX:EBR) is boosting its balance sheet with firm commitments to raise $55.9 million through an institutional placement. EBR is also set to undertake a $6m share purchase plan to eligible shareholders. Together, the company will raise nearly $62m to progress commercialisation of its WiSE CRT system, the world's first and only wireless solution for pacing the left side of the heart. The raise follows US Food and Drug Administration (FDA) approval for WiSE in April. Oncology focused biotech Chimeric Therapeutics (ASX:CHM) has received firm commitments to raise $6.6m through a two-tranche placement to institutional, sophisticated and professional investors with cornerstone support from a US-based family office. Funding will focus on progressing CHM CDH17, a pioneering third-generation CAR T-cell therapy that targets the CDH17 protein as well as advancing its CORE-NK clinical trials. Developer of a new class of synthetic anti-infectives Recce Pharmaceuticals (ASX:RCE) has raised $8.4m raised across an entitlement offer and placement to support phase III registrational trials, which it said was the catalyst for revenue in CY26. And Island Pharmaceuticals (ASX:ILA) has raised $3.6m through a placement, including $100,000 subscribed for by directors subject to shareholder approval. Island said funding would provide flexibility to advance its lead asset ISLA-101 pending results from the phase 2a/b PROTECT trial in dengue fever. This includes potential progression to a larger phase II trial in key international regions where the mosquito-borne infection is highly prevalent. Mayne Pharma takeover wobbles as ASX healthcare rises Mayne Pharma (ASX:MYX) has sold off this week amid concerns its takeover deal could collapse. US-based Cosette Pharmaceuticals initiated a review of its ~$672m acquisition, citing a "material adverse change" in the Australian firm's business and finances. Mayne shareholders were due to vote on the court-approved scheme of arrangement on June 18. "I am presuming the vote will go ahead but there are a few issues to contend with," Power said. Meanwhile, the ASX healthcare sector is up for the week as the Reserve Bank of Australia (RBA) cut the cash rate by by 25bps to 3.85%. At 12.45pm (AEST) on Friday the S&P/ASX 200 Health Care index was up 0.57%% for the past three days, while the benchmark ASX 200 rose 0.35% for the same period. "It's been a more positive week and the lower interest rates does help move money back into the growth stocks and are better for equity markets generally," Power said. Monash downgrades FY25 profit guidance After confirming in April it had mistakenly implanted a woman with the wrong embryo resulting in the birth of a child, the woes for Monash IVF Group (ASX:MVF) continue with the company downgrading its FY25 guidance. Underlying NPAT is now expected to be $27.5 million from previous guidance of $30-31m. The downgrade was attributed to a softer market and operating conditions across all geographic markets in March, that worsened in April. Monash said May improved but not enough to offset weakness in the previous two months. "We suspect a number of factors were at play in April, including lower consumer sentiment (macro factors), impact of timing of Easter/ Anzac Day holidays and the lead-up to the election," Morgans' lead analyst on Monash Emily Porter wrote in a note to clients. "We also suspect Victoria continues to be the troublesome state, driven by weaker industry cycles (down ~10% taking a 4-month average to March) and we suspect possible market share loss in the region." Monash said it continued to monitor movements in new patient registrations, returning IVF patients, transfers to alternative providers (across Queensland and Australia) noting that performance since news of the Brisbane incident broke in April had been consistent with the months leading up to this date. "We see this as positive but think these will be important metrics to track in the coming 3-6 months," Porter wrote. "Interestingly, MVF did not provide an update on the findings of the independent report by Fiona McLeod AO SC into the incident. "Without clarity on the outcome of this review, we continue to see this as a likely overhang on the stock. Morgans have downgraded its NPAT forecasts for FY25 by 11% from $30.6m to $27.5m in line with updated guidance and have also lowered its NPAT forecasts for FY26/27 by 15%/16% respectively. "We have reduced our domestic cycle volumes driven by lower industry cycles and some loss of market share in FY26/27," Porter wrote. Morgans has upgraded its rating to a speculative buy but based on downward revisions to earnings reduced its 12-month target price from $1.34 to $1. Power's Powerplay: EMVision advances AI-driven stroke diagnostics Neurodiagnostics medical devices company EMvision Medical Devices (ASX:EMV) is Power's stock of the week after announcing it had advanced its AI-driven stroke diagnostics. Promising new data showing enhanced performance of its 'ischemia or not' algorithm was this week presented at the 11th European Stroke Organisation Conference (ESOC 2025) in Helsinki, Finland. EMVision said the emu RF-based model missed only one case in a limited sensitivity analysis of 20 ischemic test cases, compared to nine missed using first-line Non-Contrast Computed Tomography (NCCT). "They're basically adding AI to improve the learning of their emu product," Power said. EMVision have improved the sensitivity – the ability of the device to diagnose a disease – and the specificity, which is the ability to rule out false positives. "Previously the sensitivity was 85% and specificity 78%," Power said. "In the updated dataset the algorithm's performance has improved to 95% sensitivity and 80% specificity." EMVision said the recently started pivotal trial of its emu bedside brain scanner for diagnosing stroke to support US Food and Drug Administration (FDA) de novo (new device) clearance had been designed to also validate algorithm performance. Clarity kicks off phase III trial for prostate cancer test Clarity Pharmaceuticals (ASX:CU6) has kicked off its second registrational phase III trial AMPLIFY for their diagnostic test for prostate cancer. AMPLIFY is a study of 64Cu-SAR-bisPSMA Positron Emission Tomography, a phase III trial of participants with biochemical recurrence (BCR) of prostate cancer. The trial aims to investigate the ability of 64Cu-SAR-bisPSMA PET/computed tomography (CT) to detect recurrence of prostate cancer and will enrol ~220 participants at multiple clinical sites across the US and Australia. As a pivotal trial, the final results are intended to provide sufficient evidence to support an application to the US Food and Drug Administration (FDA) for approval of 64Cu-SAR-bisPSMA as a new diagnostic imaging agent in BCR of prostate cancer. "It's another good news story for the sector this week," Power said. Oral OSA drug not a 'major disruptor' to ResMed's CPAP tech ResMed (ASX:RMD) saw its share price retreat on Tuesday but recover the next day after privately held US pharma company Apnimed released top-line results from a phase III trial (SynAIRgy) evaluating lead candidate AD109 targeting obstructive sleep apnoea (OSA). AD109 is an oral drug that targets neurological pathways that contribute to airway collapse during sleep, in adults living with mild, moderate and severe OSA. The trial met its primary endpoint, which was mean change from baseline in the apnoea-hypopnea index (AHI) at 26 weeks. AD109 also demonstrated improvements in other secondary and exploratory endpoints. In a note to clients Morgans' healthcare analyst Derek Jellinek wrote that he was not too concerned about the effects of the trial on leader in sleep-related respiratory disorders ResMed. "While the study demonstrates AD109 is having an impact on OSA, consistent with prior trials, only top-line results were reported, so there is inadequate detail to determine extent of improvement on a per patient basis," he wrote. "It remains unknown in which patients the drug was most effective and best tolerated and how long the effect lasts." Although AD109 offers a non-invasive, oral alternative to OSA and continues to show promise in trials, Jellinek wrote Morgans have never viewed the drug as a "major disruptor to gold standard CPAP" (continuous positive airway pressure) therapy, especially for patients with moderate to severe cases. He said it may more likely be an option for those who cannot tolerate CPAP or with mild to moderate OSA, so unlikely to be a substitute for CPAP entirely. "We continue to view RMD in a strong competitive position, with technological offerings driving greater adoption of its products, along with its US tariff exemption status and added benefits from favourable trends in wearables and weight loss drugs," he wrote. Morgans has an add rating on Resmed and a 12-month target price of $44.07. The views, information, or opinions expressed in the interview in th is article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While EBR Systems, Island Pharmaceuticals, Recce Pharmaceuticals and EMVision Medical Devices are Stockhead advertisers, the companies did not sponsor this article.
